Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease (Adv. Mater. 51/2023)

Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease (Adv. Mater. 51/2023)

Brain‐Targeted Liposomes In article number 2304654, Avi Schroeder and co‐workers describe a targeted nanotechnology drug delivery system for treating Parkinson's disease. Brain‐targeted liposomes—nanoparticles engineered with transferrin on their surface and carry therapeutic antibodies, cross...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Weinheim) 2023-12, Vol.35 (51), p.n/a
Hauptverfasser: Sela, Mor, Poley, Maria, Mora‐Raimundo, Patricia, Kagan, Shaked, Avital, Aviram, Kaduri, Maya, Chen, Gal, Adir, Omer, Rozencweig, Adi, Weiss, Yfat, Sade, Ofir, Leichtmann‐Bardoogo, Yael, Simchi, Lilach, Aga‐Mizrachi, Shlomit, Bell, Batia, Yeretz‐Peretz, Yoel, Or, Aviv Zaid, Choudhary, Ashwani, Rosh, Idan, Cordeiro, Diogo, Cohen‐Adiv, Stav, Berdichevsky, Yevgeny, Odeh, Anas, Shklover, Jeny, Shainsky‐Roitman, Janna, Schroeder, Joshua E., Hershkovitz, Dov, Hasson, Peleg, Ashkenazi, Avraham, Stern, Shani, Laviv, Tal, Ben‐Zvi, Ayal, Avital, Avi, Ashery, Uri, Maoz, Ben M., Schroeder, Avi
Format: Artikel
Sprache:eng
Schlagworte:
Blood-brain barrier
brain targeting
central nervous system
Drug delivery systems
lipid nanoparticles
Liposomes
Materials science
Monoclonal antibodies
neuroinflammation
Parkinson's disease
Signs and symptoms
Transferrin
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Brain‐Targeted Liposomes In article number 2304654, Avi Schroeder and co‐workers describe a targeted nanotechnology drug delivery system for treating Parkinson's disease. Brain‐targeted liposomes—nanoparticles engineered with transferrin on their surface and carry therapeutic antibodies, cross the blood–brain barrier and effectively treat brain neurodegeneration. This approach reduces pathological alpha‐synuclein aggregation and improves motor skills, demonstrating its potential for treating neurodegenerative diseases.
ISSN:0935-9648
1521-4095
DOI:10.1002/adma.202370367